Clinics in Dermatology
Volume 27, Issue 6 , Pages 603-613 , November 2009

Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma

  • Swagatam Ray, PhD

      Affiliations

    • Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, L-3080, Farmington, CT 06030, USA
    • ,
  • Arvind Chhabra, PhD

      Affiliations

    • Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, L-3080, Farmington, CT 06030, USA
    • ,
  • Shikhar Mehrotra, PhD

      Affiliations

    • Division of Surgery, Medical University of South Carolina, Hollings Cancer Center, 86 Jonathan Lucas Street, Suite 512, Charleston, SC 29425, USA
    • ,
  • Nitya G. Chakraborty, PhD

      Affiliations

    • Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, L-3080, Farmington, CT 06030, USA
    • ,
  • Antoni Ribas, MD

      Affiliations

    • Departments of Surgery and Medicine, University of California, Los Angeles, School of Medicine, 10833 Le Conte Avenue, Room 54-140 CHS, Los Angeles, CA 90095, USA
    • ,
  • James Economou, MD, PhD

      Affiliations

    • Departments of Surgery and Medicine, University of California, Los Angeles, School of Medicine, 10833 Le Conte Avenue, Room 54-140 CHS, Los Angeles, CA 90095, USA
    • ,
  • Bijay Mukherji, MD

      Affiliations

    • Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, L-3080, Farmington, CT 06030, USA
    • Corresponding Author InformationCorresponding author.

References 

  1. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A. 1995;92:8079–8082
  2. Ribas A, Butterfield LH, Glasoy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2414–2432
  3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–915
  4. Ehrlich P. Nederlandsch tijdscrift voor geneeskunde: Uber den jetzigne stand der karzinom-forschung. Weekblad Jaargang Eerst Heft. 1909;5:273–290
  5. Mukherji B. Molecular basis for tumor immunity. In:  Bertino JR editors. Encyclopedia of cancer, volume 3. Orlando: Academic Press, Inc; 2002;p. 197–212
  6. Mukherji B, MacAlister TJ. Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med. 1983;158:240–245
  7. Knuth A, Danowski B, Oettgen HF, Old LJ. T cell mediated cytotoxicity against autologous malignant melanoma: analysis with Inteerleukin-2 dependent T cell cultures. Proc Natl Acad Sci U S A. 1984;81:3511–3515
  8. Van der Bruggen P, Traversari P, Chomez P, et al. A gene encoding n antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1996;183:725–729
  9. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992;176:1453–1457
  10. Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol. 2008;66:52–64
  11. Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky D, Chakraborty NG, Mukherji B. Rescuing epitope specific cytolytic T lymphocytes from activation induced cell death by SP6000125, an inhibitor of Jun- N-terminal kinase: implication in cancer immunotherapy. J Immunol. 2004;173:6017–6024
  12. Mehrotra S, Chhabra A, Hegde U, Chakraborty NG, Mukherji B. Inhibition of c-Jun N-terminal kinase rescues influenza epitope specific human cytolytic T lymphocytes from activation induced cell death. J Leuk Biol. 2007;81:539–547
  13. Lenardo MJ. Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system. Immunol Res. 2003;27:387–398
  14. Chhabra A, Mehrotra S, Chakraborty NG, Dorsky DI, Mukherji B. Activation induced cell death of human melanoma epitope specific primary cytolytic T lymphocytes mediated by the release of mitochondrial apoptosis inducing factor. Eur J Immunol. 2006;3:3167–3174
  15. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548
  16. Barber DL Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687
  17. Gershon RK, Kondo K. Infectious immunological tolerance. Immunol. 1971;21:903–914
  18. North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1–43
  19. Mukherji B, Wilhelm SA, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol. 1986;136:1888–1892
  20. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–549
  21. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cell and tumor immunity. Cancer Immunol Immunother. 2005;54:1153–1161
  22. Chattopadhyay S, Mehrotra S, Chhabra A, Chakraborty NG, Mukherji B. Effect of CD4+CD25+ and CD4+CD25- regulatory T cells on the activation and expansion of self epitope and non-self epitope specific CTL precursors, in vitro. J Immunol. 2004;176:984–990
  23. Nagaraj S, Gabrilovich D. Myeloid-derived suppressor cells. Adv Exp Med Biol. 2007;601:213–223
  24. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–169
  25. Sprent J, Surh CD. Generation and maintenance of memory T cells. Curr Opin Immunol. 2001;13:248–254
  26. Kaplan BL, Tu DC, Clay TM, Nishimura MI. Redirecting T lymphocyte specificity using T cell receptor genes. Int Rev Immunol. 2003;170:4881–4885
  27. Morris EC, Tsallios A, Bendle GM, Xue S, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A. 2005;102:7934–7939
  28. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that mediated by tumor cells. Annu Rev Immunol. 2007;5:267–296
  29. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998

☆ This work was supported by PHS grants CA 83130 (BM), UCHC GCRC grant MO1RR06192, CA129816 (JSE), and grants from the Dowling Foundation (BM), Samuel Waxman Foundation, and WM Keck Foundation (JSE) for the UCLA-CALTECH-CHLA-USC-UCONN consortium on translational Program in Engineered Immunity.

PII: S0738-081X(08)00196-X

doi: 10.1016/j.clindermatol.2008.09.019

Clinics in Dermatology
Volume 27, Issue 6 , Pages 603-613 , November 2009

Article Tools

* Image Usage & Resolution